SS
CUE icon

SBI Securities’s Cue Biopharma CUE Stock Holding History

SBI Securities’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.47K Buy
+300
New +$6.78K ﹤0.01% 1862
2025
Q4 		– Hold
0
– -$1 – 4077
2025
Q3 		– Hold
0
– – – 4168
2025
Q1 		– Hold
0
– -$1 – 4148
2024
Q4 		– Hold
0
– – – 4073

Other funds holding CUE

RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SBI Securities's CUE Position: Q2 2026 in Review

SBI Securities opened a new position in Cue Biopharma (CUE) in Q2 2026: 300 shares worth $9.47K. The stake represents ﹤0.01% of the portfolio and ranks #1862 among its holdings.

8 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • SBI Securities held 300 shares of Cue Biopharma worth $9.47K as of Q2 2026.
  • Cue Biopharma was a new SBI Securities position in Q2 2026.
  • Cue Biopharma made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1862 holding.
  • 8 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.